Kim joined Takeda in 2019 through the acquisition of Shire, where she held several roles with increasing responsibility. She became the president of the Plasma-Derived Therapies business unit and held this position until April 2022, when she became president of the US business unit and US country head.

With three decades working in health care and leadership positions at global, regional, country and functional levels, her experiences cover a variety of therapeutic areas, international market access, country and regional general management, marketing and emerging market development.

Kim earned an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree in economics from Dartmouth College.